The short version
- A phase III clinical trial is recruiting healthy middle-aged adults to test whether an experimental drug can prevent Alzheimer’s disease before dementia symptoms emerge.
- Participants will be screened using a blood test for p-tau217, a biomarker associated with high accuracy in predicting cognitive decline and Alzheimer’s development.
- The study investigates Trontinemab, a Roche-developed therapy that targets amyloid plaques, aiming to determine if early intervention can halt the disease process.
A significant shift in dementia research is underway as a major international clinical trial begins recruiting participants who show no signs of memory loss. The study, known as PrevenTRON, aims to determine whether an experimental medication can prevent Alzheimer’s disease before cognitive impairment becomes apparent. This approach represents a departure from traditional methods that focus on treating patients after symptoms have already manifested, addressing the long-standing challenge of intervening too late in the disease progression.
The trial is currently screening its first European participants through the Surrey and Borders Partnership NHS foundation trust. Recruitment efforts are targeting approximately 1,600 individuals aged between 55 and 80 from various locations around the world. These candidates must be healthy middle-aged adults deemed to be at higher risk for developing the condition but who currently exhibit no memory problems. The initial screening process involves rigorous testing to confirm the absence of cognitive issues before proceeding to more specific biomarker analysis.
Central to the selection process is a blood test designed to measure levels of p-tau217, a protein biomarker linked to Alzheimer’s pathology. Previous studies have indicated that this marker can identify the disease with up to 95% accuracy. Research has also shown that individuals with the highest concentrations of p-tau217 face an estimated 78% probability of developing cognitive impairment within a decade. By focusing on this biological indicator, researchers hope to identify those who are in the preclinical stages of the disease, allowing for earlier intervention.
The medication under investigation is Trontinemab, developed by the Swiss pharmaceutical company Roche. This drug targets amyloid plaques, toxic protein deposits that accumulate in the brain and contribute to the death of brain cells. Early research into Trontinemab has been promising, with data suggesting it cleared these plaques in nine out of ten people with early-stage Alzheimer’s or mild cognitive impairment within 28 weeks. The PrevenTRON trial seeks to establish whether this mechanism can effectively stop dementia from developing in individuals who have not yet shown clinical symptoms.
Participants in the study will be randomly assigned to receive either Trontinemab or a placebo. They will then be monitored over a period expected to last between four and six years. The primary goal is to observe how quickly, if at all, signs of dementia develop in each group. This long-term monitoring is crucial for understanding whether the removal of amyloid plaques translates into sustained cognitive preservation. At least 15 hospitals and clinics across the UK are anticipated to join the study by the end of the year, expanding the reach of the recruitment effort.
Professor Ramin Nilforooshan, a consultant psychiatrist and the chief investigator for the trial, emphasized the experimental nature of the work. He noted that while the shift from cure to prevention is a critical step forward, there are no guarantees regarding the drug’s efficacy in this specific context. The study addresses whether acting earlier, before symptoms begin, can alter the trajectory of the disease. This cautious optimism reflects the broader scientific community’s recognition that preventing neurodegeneration is a complex challenge requiring robust evidence.
The urgency of such research is underscored by the prevalence of Alzheimer’s disease in older populations. Statistics indicate that the condition affects roughly one in 14 people over the age of 65 and one in six individuals over the age of 80. Current understanding suggests that the disease process begins inside the brain up to a decade before patients typically seek treatment for memory problems. By targeting this silent period, researchers aim to intervene when therapeutic options may be most effective.
If successful, this trial could pave the way for new strategies in dementia care, potentially helping millions of people worldwide. However, the results will not be immediate, given the multi-year timeline required to monitor participants. The outcome will provide critical data on whether biomarker-guided prevention is a viable strategy for combating Alzheimer’s. Until then, the medical community awaits evidence that early intervention can truly halt the progression of this devastating condition.
Sources behind this briefing
Go to the original reporting
- The Guardian World↗Alzheimer’s trial to test drug on people without symptoms to see if it can be prevented
